3 results about "Propranolol" patented technology

The invention provides propranolol temperature-sensitive hydrogel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The propranolol temperature-sensitive hydrogel disclosed by the invention is prepared from chitosan-beta-sodium glycerophosphate hydrogel and nano microspheres loaded on the chitosan-beta-sodium glycerophosphate hydrogel, wherein the chitosan-beta-sodium glycerophosphate hydrogel is a chitosan-beta-sodium glycerophosphate hydrogel; the nano microspheres are chitosan microspheres which are used for encapsulating propranolol; the mass of the nano microspheres is 1%-20% of the mass of the chitosan-beta-sodium glycerophosphate hydrogel. The propranolol temperature-sensitive hydrogel provided by the invention is a dual slow-release temperature-sensitive hydrogel system, not only has remarkable controlled release performance, can release drugs more continuously and stably, but also has good drug loading property and stable rheological property.

The invention provides application of propranolol or pharmaceutically acceptable salts thereof in preparation of drugs for inhibiting lung cancer meningeal metastasis. The invention discloses the application of blocking neuroendocrine differentiation in prevention and treatment of tumor meningeal metastasis for the first time, the neuroendocrine differentiation of lung cancer is blocked by propranolol, and the survival ability of lung cancer cells in a cerebrospinal fluid environment can be weakened, so that the lung cancer meningeal metastasis is inhibited, and the lung cancer is finally improved or treated. Neuroendocrine differentiation is found to be a key regulation factor of lung cancer meningeal metastasis, and potential development prospects are achieved by blocking lung cancer neuroendocrine differentiation through propranolol so as to inhibit lung cancer meningeal metastasis.

This invention discloses the application of GLPG0187 in combination with propranolol in the preparation of drugs for the treatment or inhibition of hemangiomas. GLPG0187 is an integrin β1 inhibitor, and propranolol is a β-receptor blocker. This invention was validated through CCK8 assays, scratch assays, and tube formation assays. The results showed that, compared with propranolol monotherapy, GLPG0187 (4 nM) combined with propranolol (20-30 μM) could further inhibit the proliferation, migration, and tube formation ability of human hemangioma endothelial cells, demonstrating superior efficacy compared to propranolol monotherapy. This invention addresses the issue that approximately 2.1% of patients treated with propranolol monotherapy for infantile hemangiomas experience side effects such as sleep disturbances, bronchospasm, and hypoglycemia, providing a new combination therapy regimen and offering a new drug option for reducing the clinical dosage of propranolol and minimizing the risk of side effects. This invention identifies a new target for the treatment of hemangiomas, providing new possibilities for hemangioma treatment.